AstraZeneca PLC: EPS $2.79 vs $2.60 expected; revenue $16.2B vs $16.0B
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 2.79 | 2.60 | +7.3% | 2.38 |
| Revenue (USD bn) | 16.21 | 16.00 | +1.3% | 15.19 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Q3 FY2026 | 2.79 | 2.60 | +7.3% | 16.21 | 16.00 | +1.3% |
| Jul 27, 2026 | Q2 FY2026 | 2.63 | 2.50 | +5.2% | 15.38 | 15.44 | −0.3% |
| Apr 29, 2026 | Q1 FY2026 | 2.58 | 2.57 | +0.4% | 15.29 | 14.93 | +2.4% |
| Feb 10, 2026 | Q4 FY2025 | 2.12 | 2.09 | +1.4% | 15.50 | 15.44 | +0.4% |
| Nov 6, 2025 | Q3 FY2025 | 2.38 | 2.29 | +3.9% | 15.19 | 14.78 | +2.8% |
| Jul 29, 2025 | Q2 FY2025 | 2.18 | 2.16 | +0.9% | 14.46 | 14.10 | +2.5% |
| Apr 29, 2025 | Q1 FY2025 | 2.48 | 2.25 | +10.2% | 13.59 | 13.81 | −1.6% |
| Feb 6, 2025 | Q4 FY2024 | 2.10 | 2.07 | +1.4% | 14.89 | 14.23 | +4.7% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures.
AstraZeneca PLC results: EPS $2.79 vs $2.60 expected; revenue $16.2B vs $16.0B. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 7.3%; revenue above the estimate by 1.3%.
Revenue was up 6.7% from $15.2 billion a year earlier (Q3 FY2025). EPS was up 17.2% from $2.38 a year earlier. On its record, EPS topped analysts' estimates in 7 of 7 earlier comparable reports.
What the results mean
AstraZeneca PLC's business rests on a medicines portfolio spanning oncology, cardiovascular, renal, metabolic and rare diseases. This diversity provides multiple sources of demand, while the commercial value of its treatments depends on patient access and physician adoption.
The company's business model covers drug discovery, development, manufacturing and commercialization, making research efficiency and commercial execution interconnected drivers of performance. Its research collaborations support treatment discovery and development, while research spending, manufacturing capabilities and distribution remain important to understanding profitability.
What to watch on the earnings call: Listen for management's discussion of demand across therapeutic areas, patient access and physician adoption. The relationship between research spending and margins also merits attention, alongside progress in development programs and collaborations toward commercially viable treatments.
For the full analysis of AstraZeneca PLC stock — valuation, scores and financial statements — see the stock page linked with this story.